ERBB2 and gastric cancer: Recent advances in treatment of Her-2/neu-overexpressing GC/GEJ cancer led to the approvals for Enhertu® (January 2021) in patients who have progressed on trastuzumab containing treatment and Keytruda® (May 2021) as 1L treatment in combination with trastuzumab and chemotherapy in patients with HER2/neu-overexpressing advanced or metastatic GC/GEJ cancer (7, 8).